RAAS inhibition and cardiorenal syndrome

Current Hypertension Reviews

Volumn 10, Issue 2, 2014, Pages 107-111

  Onuigbo, Macaulay Amechi C ^a,b  

^a Mayo Clinic   (United States)

^b Mayo Clinic Health System   (United States)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Cardiorenal syndrome; RAAS inhibition; Unintended consequences

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM BLOCKER; UNCLASSIFIED DRUG; URINARY TRACT AGENT;

ARTICLE; CARDIORENAL SYNDROME; CONSENSUS; DISEASE CLASSIFICATION; DRUG MECHANISM; EVIDENCE BASED PRACTICE; HUMAN; MOLECULAR PATHOLOGY; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CARDIO-RENAL SYNDROME; CARDIOVASCULAR DISEASES; COMPLICATION; CONSENSUS DEVELOPMENT; DRUG EFFECTS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIO-RENAL SYNDROME; CARDIOVASCULAR DISEASES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84921775017     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/1573402111666141231144228     Document Type: Article

References (58)

1. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31(6): 703-11.
2. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-62.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 2 1): S1-S266.
4. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422-30.
5. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002; 8: 509-14.
6. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-47.
7. NHLBI Working Group: Cardio-Renal Connections in Heart Failure and Cardiovascular Disease. August 2004. Available at http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm.
8. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341(8): 577.
9. Sarraf M1, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4(12): 2013-26.
10. Kiernan MS, Udelson JE, Sarnak M, Konstam M. Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2013.
11. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart-failure — relationship of cardiac index to kidney-function. Drugs 1990; 39: 10-21.
12. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. EurJ Heart Fail 2007; 9(9): 872-8.
13. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intraabdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008; 51(3): 300-6.
14. Wencker D. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure. Curr Heart Fail Rep 2007; 4(3): 134.
15. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988; 1(8593): 1033-5.
16. Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC. Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension 1992; 19: 137-41.
17. Blair JE, Manuchery A, Chana A, et al. Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care 2007; 9(4): 207-13.
18. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol 1931; 72: 49-61.
19. Bock JS, Gottlieb SS. Cardiorenal Syndrome New Perspectives. Circulation 2010; 121: 2592-600.
20. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311(13): 819.
21. Colucci WS. Pathophysiology of heart failure: Neurohumoral adaptations. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA, 2013.
22. Harrison-Bernard LM. The renal renin-angiotensin system Adv Physiol Educ 2009; 33(4): 270-4.
23. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
24. Taal M, Tomson C. Clinical practice guidelines. Module 1. Chronic kidney disease. Clinical Practice Guidelines for the Care of Patients with Chronic Kidney Disease. UK Renal Association Clinical Practice Guidelines. 4th Edition 2007. Final Version. http://www. renal.org/docs/default-source/guidelines-resources/Module_1_-_Chronic_Kidney_Disease_CKD_-_4th_Edition.pdf accessed April 4, 2014. Posted at www.renal.org/guidelines in March 2007.
25. Cassidy M, Richardson D, Jones C. Clinical practice guidelines. Module 2: Complications. UK Renal Association. Fourth Edition, 2007. Final Version. http://www.renal.org/docs/default-source/guidelines-resources/Module_2_-_Complications_-_4th_Edition.pdf accessed April 4, 2014. Posted at www.renal.org/guidelines in December 2007.
26. Okechukwu CN, Tasem M. Use of ACE-Inhibitors and Angiotensin-2 Receptor Blockers in the Management of the Cardio-Renal Syndrome. In: Macaulay Amechi Chuka Onuigbo, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 2. New York, NY. NOVA Publishers, 2013.
27. Rubattu S, Mennuni S, Testa M, et al. Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? Int J Mol Sci 2013; 14(11): 23011-32.
28. Du Y, Li X, Liu B. Advances in pathogenesis and current therapeutic strategies for cardiorenal syndrome. Life Sci 2014; 99(1-2): 1-6.
29. Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996; 5: 89-96.
30. Warren DJ, Ferris TF. Renin secretion in renal hypertension. Lancet 1970; 1: 159-62.
31. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J 2005, 26, 11-7.
32. Gnanaraj JF, von Haehling S, Anker SD, Raj DS, Radhakrishnan J. The relevance of congestion in the cardio-renal syndrome. Kidney Int 2013; 83(3): 384-91.
33. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16): e147-239.
34. Onuigbo M., Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 2005; 11(10): CR462-9.
35. Onuigbo M., Onuigbo NT. Use of ultrahigh RAAS blockade: implications for exacerbation of renal failure. Kidney Int 2006; 69(1): 194-5.
36. Onuigbo M., Onuigbo NT. Late-onset renal failure from RAAS blockade. Kidney Int 2006; 70(7): 1378-9.
37. Onuigbo M., Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40(1): 233-9.
38. Onuigbo M., Onuigbo NT. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors. Ren Fail 2008; 30(1): 73-8.
39. Onuigbo M., Achebe NJ. Late Onset Renal Failure From Angiotensin Blockade (LORFFAB) – The Results of a Mayo Clinic Health System Angiotensin Inhibition Withdrawal Study: A Clarion Call For More Preventative Nephrology, Also Called Renoprevention. In: Macaulay Amechi Chuka Onuigbo, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 1. New York, NY. NOVA Publishers, 2013.
40. Ahmed AK, Kamath NS, El Kossi M, et al. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25(12): 3977-82.
41. Gonçalves AR, Khwaja A, Ahmed AK, El Kossi M, El Nahas M. Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response. Nephron Clin Pract 2011; 119(4): c348-54.
42. Onuigbo MA. Renoprevention Revisited - The Impact of Preemptive Withdrawal of RAAS Blockade prior to Iodinated Contrast Exposure in Older CKD Patients: Results of a New Meta- Analysis. Cardiology 2014; 130: 25-6.
43. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensinconverting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4(6): 685-91.
44. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1992; 325: 293-302.
45. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study Trial). Am J Cardiol 1992; 70: 479-87.
46. Geisberg C, Butler J. Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med 2006; 73(5): 485-91.
47. Ross EA. Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail 2012; 18(12): 930-8.
48. Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man. J Clin Invest 1947; 26: 1010e22.
49. Testani JM, Khera AV, St John Sutton MG, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; 105: 511e6.
50. Bonfim RF, Goulart AG, Fu C, Torquato JA. Effect of hemodialysis on intra-abdominal pressure. Clinics (Sao Paulo) 2007; 62: 145e50.
51. Nakayama M, Nakano H. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol 2010; 55: 49e54.
52. Sotirakopoulos NG, Kalogiannidou IM, Tersi ME, Mavromatidis KS. Peritoneal dialysis for patients suffering from severe heart failure. Clin Nephrol 2011; 76: 124e9.
53. Sanchez JE, Ortega T, Rodrıguez C, et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 2010; 25: 605e10.
54. Shchekochikhin D, Schrier RW, Lindenfeld J. Cardiorenal syndrome: pathophysiology and treatment. Curr Cardiol Rep 2013; 15(7): 380.
55. Hawwa N, Schreiber MJ Jr, Tang WH. Pharmacologic management of chronic reno-cardiac syndrome. Curr Heart Fail Rep 2013; 10(1): 54-62.
56. Lazzarini V, Felker GM. Management of the cardiorenal syndrome in acute heart failure. Curr Treat Options Cardiovasc Med 2012; 14(4): 342-55.
57. Onuigbo M. Renoprotection and the Bardoxolone Methyl Story - Is this the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A new classification scheme for renoprotective agents. Nephron Extra 2013; 3: 36-49.
58. Onuigbo MA. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs 2014; 23(6): 883-4.